Nutrition Department, Ragle Facility, University of California Davis
Davis, California, 95616, United States
NCT Number: NCT06944210
This study aims to evaluate the antioxidant and anti-inflammatory effects of acute and chronic consumption of two sweet orange (Citrus sinensis) varieties-'Rosy Red Valencia', which is rich in carotenoids such as lycopene, phytoene, and phytofluene, and 'Olinda Valencia', which lacks these carotenoids-in healthy adults. In this 4-week, randomized, parallel-arm clinical trial, participants will consume either 'Rosy Red Valencia' or 'Olinda Valencia' oranges daily. The study will assess the effects of sweet orange intake on markers of oxidative stress and inflammation, plasma carotenoid concentrations, gene expression in peripheral blood mononuclear cells, and gut health. Findings from this study may help identify potential health benefits associated with specific carotenoid profiles in sweet oranges and provide insights into their role in modulating inflammation and oxidative stress.
Looking for future studies?
Notify Me25 year–40 year
All sexes
Interventional
Not applicable
Davis, California, 95616, United States
The health benefits of orange consumption have been described; however, the specific bioactive compounds responsible for these effects, as well as the underlying mechanisms of action, are not fully understood. There are several varieties of sweet oranges, each with a unique phytochemical profile and potentially distinct health-promoting properties. The 'Rosy Red Valencia' sweet orange is enriched in carotenoids such as lycopene, phytoene, and phytofluene, whereas the commonly consumed 'Olinda Valencia' contains negligible levels of these compounds.
This randomized, parallel-arm clinical trial aims to evaluate and compare the antioxidant and anti-inflammatory effects of 'Rosy Red Valencia' and 'Olinda Valencia' sweet orange consumption in healthy men and women. Participants will be randomized to consume one of the two orange varieties twice daily for four weeks.
The study includes both an acute phase (1-day consumption) and a chronic phase (4-week daily consumption). Blood samples will be collected at baseline, after 1 day, and after 4 weeks of consumption to assess changes in plasma carotenoid concentrations, markers of oxidative stress and inflammation, and gene expression profiles in peripheral blood mononuclear cells. Fecal samples will be collected at baseline and after 4 weeks to assess the effects on gut microbiota composition. By evaluating and comparing the biological effects of these two orange varieties, the study aims to elucidate the role of specific carotenoids in mediating the health benefits of sweet orange consumption.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The participants consume 2 'Rosy Red Valencia' sweet oranges daily for 4 weeks
The participants consume 2 'Olinda Valencia' sweet oranges daily for 4 weeks
Time frame: 0, 1 day, 4 weeks
Levels in plasma
Time frame: 0, 1 day, 4 weeks
Oxidative stress marker DNA/RNA oxidative damage assessed in blood samples from participants by a commercial kit
Time frame: 0, 1 day, 4 weeks
Levels of inflammatory marker CRP assessed in blood samples from participants using commercial assay kits.
Time frame: 0, 1 day, 4 weeks
Gene expression in Peripheral Blood Mononuclear Cells (PBMCs)
Time frame: 0, 4 weeks
From stool samples
Time frame: 0, 4 weeks
Measured in blood samples
Time frame: 0, 4 weeks
Measured by automated sphygmomanometer
University of California, Davis
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07008586
Behavior, Healthy
Cambridge, United Kingdom
View Trial DetailsNCT06041087
Behavior, Bone
Toronto, Ontario, Canada
View Trial DetailsNCT05746845
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Orléans, France
View Trial DetailsNCT07072520
Female, Healthy
Ankara, Çubuk, Turkey (Türkiye)
View Trial Details